Skip to Content

What type of drug is Emgality?

Answers (1)

Official Answer by Drugs.com 7 Nov 2018

Eli Lilly’s Emgality (galcanezumab-gnlm) is a calcitonin gene-related peptide (CGRP) antagonist, and the third drug approved in this new class for migraine prevention in adults. When CGRP binds to its receptor, a cascade of events such as vasodilation and protein leakage begin that results in inflammation and pain associated with migraine.

Dosing for Emgality is 120 mg given once monthly by subcutaneous (under the skin) injection after an initial, one-time, 240 mg loading dose.

Emgality joins the previously approved CGRP antagonists Ajovy (fremanezumab-vfrm) from Teva Pharmaceutical and Aimovig (erenumab-aooe) from Amgen.

How do calcitonin gene-related peptide (CGRP) antagonists work?

  • Emgality and Ajovy work similarly: they bind to the CGRP ligand and block its binding to the receptor to help prevent migraine pain.
  • Aimovig actually selectively binds to the CGRP receptor (not the ligand) to block CGRP activation, thereby preventing migraine pain.
Drugs.com free discount card

Further Information

Search for questions

Still looking for answers? Try searching for what you seek or ask your own question.

Frequently Asked Questions

What type of drug is Motegrity?

Updated 16 days ago 1 answerFAQ by Drugs.com

What disease is Elzonris (tagraxofusp-erzs) used to treat?

Updated 13 days ago 1 answerFAQ by Drugs.com

How do you use the ProAir Digihaler?

Updated 13 days ago 1 answerFAQ by Drugs.com

How many biosimilars have been approved in the United States?

Updated 12 days ago 1 answerFAQ by Drugs.com